WO2016122289A3 - 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물 - Google Patents

베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물 Download PDF

Info

Publication number
WO2016122289A3
WO2016122289A3 PCT/KR2016/001093 KR2016001093W WO2016122289A3 WO 2016122289 A3 WO2016122289 A3 WO 2016122289A3 KR 2016001093 W KR2016001093 W KR 2016001093W WO 2016122289 A3 WO2016122289 A3 WO 2016122289A3
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
side effects
reperfusion procedure
composition including
verbenone derivative
Prior art date
Application number
PCT/KR2016/001093
Other languages
English (en)
French (fr)
Other versions
WO2016122289A2 (ko
Inventor
김원기
박기수
송화영
주청
Original Assignee
고려대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고려대학교산학협력단 filed Critical 고려대학교산학협력단
Publication of WO2016122289A2 publication Critical patent/WO2016122289A2/ko
Publication of WO2016122289A3 publication Critical patent/WO2016122289A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 재관류 시술에 의한 부작용을 감소 또는 예방하기 위한 약학 조성물에 관한 것으로서, 구체적으로는 화학식 1의 구조를 갖는 베르베논 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 재관류 시술에 의한 부작용을 감소 또는 예방하기 위한 조성물, 및 재관류 시술을 수행하기 전에, 이와 동시에, 또는 그 후에 상기 베르베논 유도체 또는 이의 약학적으로 허용 가능한 염을 투여함으로써 재관류 시술에 의한 부작용을 감소 또는 예방하는 방법에 관한 것이다. 또한, 본 발명은 화학식 1의 구조를 갖는 베르베논 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 재관류 시술을 받는 환자에서 뇌혈관 질환, 동맥경화증 또는 심혈관 질환을 치료하기 위한 조성물, 및 재관류 시술을 수행하기 전에, 이와 동시에, 또는 그 후에 상기 베르베논 유도체 또는 이의 약학적으로 허용 가능한 염을 투여함으로써 뇌혈관 질환, 동맥경화증 또는 심혈관 질환을 치료하는 방법에 관한 것이다.
PCT/KR2016/001093 2015-01-30 2016-02-01 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물 WO2016122289A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2015-0015215 2015-01-30
KR20150015215 2015-01-30

Publications (2)

Publication Number Publication Date
WO2016122289A2 WO2016122289A2 (ko) 2016-08-04
WO2016122289A3 true WO2016122289A3 (ko) 2016-10-27

Family

ID=56544508

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/KR2016/001092 WO2016122288A2 (ko) 2015-01-30 2016-02-01 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
PCT/KR2016/001093 WO2016122289A2 (ko) 2015-01-30 2016-02-01 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/KR2016/001092 WO2016122288A2 (ko) 2015-01-30 2016-02-01 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제

Country Status (2)

Country Link
KR (2) KR101721068B1 (ko)
WO (2) WO2016122288A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102145416B1 (ko) * 2018-09-11 2020-08-19 신풍제약 주식회사 베르베논 유도체를 포함하는 암 치료 또는 예방용 조성물
WO2022046676A1 (en) * 2020-08-24 2022-03-03 Abrexa Pharmaceuticals, Inc. Compounds for prevention and treatment of hemorrhage and vasculature instability
CN117897145A (zh) * 2021-08-30 2024-04-16 韩国新丰制药株式会社 包括马鞭草烯酮衍生物的用于治疗或预防肥胖或肥胖相关肝病的组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100366982B1 (ko) * 1994-03-25 2003-08-02 로셰 디아그노스틱스 게엠베하 혈전용해활성단백질및항응고제의조합물,및그의용도
KR20130139771A (ko) * 2012-06-05 2013-12-23 고려대학교 산학협력단 베르베논 유도체를 함유하는 퇴행성 뇌질환 치료 또는 예방용 조성물
KR20140031568A (ko) * 2012-09-04 2014-03-13 한국생명공학연구원 아실 코에이:콜레스테롤 아실 트란스퍼라제의 저해활성을 갖는 화합물 및 이를 포함하는 심혈관 질환 예방 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1312537B1 (it) * 1999-04-16 2002-04-22 Euphar Group Srl Derivati del (-)- verbenone.
US20040242565A1 (en) * 2001-09-11 2004-12-02 Yoshinori Toshima Medicinal composition for prevention of or treatment for cerebrovascular disorder and cardiopathy
EP1964556A4 (en) * 2005-12-21 2010-03-24 Shionogi & Co THERAPEUTIC AGENT OR THERAPEUTIC PROCEDURE AGAINST ISCHEMIC STROKE
RU2418577C1 (ru) * 2009-12-24 2011-05-20 Общество С Ограниченной Ответственностью "Томская Фармацевтическая Фабрика" (Ооо "Тфф") Средство для лечения болезни паркинсона
CN108969514A (zh) * 2012-01-18 2018-12-11 华鸿新药公司 佛波醇酯的组合物和使用方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100366982B1 (ko) * 1994-03-25 2003-08-02 로셰 디아그노스틱스 게엠베하 혈전용해활성단백질및항응고제의조합물,및그의용도
KR20130139771A (ko) * 2012-06-05 2013-12-23 고려대학교 산학협력단 베르베논 유도체를 함유하는 퇴행성 뇌질환 치료 또는 예방용 조성물
KR20140031568A (ko) * 2012-09-04 2014-03-13 한국생명공학연구원 아실 코에이:콜레스테롤 아실 트란스퍼라제의 저해활성을 갖는 화합물 및 이를 포함하는 심혈관 질환 예방 또는 치료용 조성물

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JU, C. ET AL.: "Discovery of Novel (1 S)-(-)-verbenone Derivatives with Anti-oxidant and Anti-ischemic Effects", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 23, no. 19, 2013, pages 5421 - 5425, XP028707922, [retrieved on 20130725] *
JU, C. ET AL.: "Up-regulation of Astroglial Heme Oxygenase-1 by a Synthetic (S)-verbenone Derivative LMT-335 Ameliorates Oxygen-glucose Deprivation- evoked Injury in Cortical Neurons", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMINICATIONS, vol. 431, no. 3, 2013, pages 484 - 489, XP028980093, [retrieved on 20130116] *

Also Published As

Publication number Publication date
KR20160094345A (ko) 2016-08-09
KR101721068B1 (ko) 2017-03-29
KR20160094344A (ko) 2016-08-09
WO2016122289A2 (ko) 2016-08-04
WO2016122288A3 (ko) 2016-11-10
WO2016122288A9 (ko) 2016-12-29
WO2016122288A2 (ko) 2016-08-04

Similar Documents

Publication Publication Date Title
WO2017132432A8 (en) Benzimidazole derivatives as modulators of ror-gamma
PH12016501394A1 (en) Compounds for treating patients with ros1 mutant cancer cells
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
NZ762034A (en) Human plasma kallikrein inhibitors
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
PH12017500444A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
WO2017053868A8 (en) C4-modified oleanolic acid derivatives for inhibition of il-17 and other uses
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
MX2015010829A (es) Compuestos terapeuticos y sus usos.
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
AU2017268795A1 (en) Methods of treating behavioral syndromes using pipradrol
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
EA201790726A1 (ru) Фармацевтическая композиция для лечения язвенного колита
EP3176163A4 (en) Novel indene derivative, preparation method for same, and pharmaceutical composition, for preventing or treating retinal diseases, containing same as active ingredient
WO2016168553A8 (en) Deuterated obeticholic acid
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
WO2015173701A3 (en) Pharmaceutical compositions comprising danirixin for treating infectious diseases
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
WO2016122289A3 (ko) 베르베논 유도체를 포함하는 재관류 시술의 부작용을 감소 또는 예방하기 위한 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16743767

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16743767

Country of ref document: EP

Kind code of ref document: A2